Generative AI and on-chip synthesis produce new LXR agonists
A recurrent neural network generated de novo LXR agonist designs, and 25 were synthesized in a microfluidic flow system. In vitro screening found 17 hits (68%), and 12 were confirmed as potent LXR agonists after batch resynthesis. Validation is in vitro only, with no in vivo testing, and the sources disagree on the number of designs retained for synthesis.
Technology: LSTM recurrent neural network generator with transfer learning, coupled to on-chip flow synthesis
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: 25 synthesized designs were screened in reporter gene assays (17 hits); 12 were confirmed as LXR agonists after batch resynthesis, with EC50 0.18 to 4.5 micromolar for LXR-alpha. No in vivo testing was reported.
- Still unknown: Chemical space was limited to one-step reactions, the primary screen used crude mixtures, two compounds were not confirmed, and the authors describe the work as proof-of-concept.
- AI role: A generative LSTM pretrained on 656,070 compounds and fine-tuned on 40 known LXR-alpha agonists, with a virtual reaction filter of 17 reaction schemes.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8195470/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 203 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.